MTX, Arava both safe, more effective than expected in JRA

MTX, arava both safe, more effective than expected in JRA
Janis INSTANCE OFactress April 20, 2007 Toronto, ONT - The rank multinational, randomized, controlled tryout to compare methotrexate with arava for discourse of juvenile rheumatoid arthritis (JRA) found both drugs to be safe and considerably more effective than had been expected.[ 1 ] The endeavor also supports the use of higher methotrexate doses than has been common. The results are published in the April 21, 2005 return of the New England Axle of Punishment . Our most important findings are that methotrexate was safe and very effective at a dose of 0.5 mg/kg per week. . . .
arava is an alternative to methotrexate and should be used in patients with JRA prior to leaving to a biologic. “Our most important findings are that methotrexate was safe and very effective at a dose of 0.15 mg/kg per week (which is higher that the dose used in some studies) and that arava had a outcome rate that was higher than expected.
arava is an alternative oral therapy for patients intolerant of methotrexate or in whom methotrexate is not effective or in patients who initially responded to methotrexate but no longer respond,” lead generator Dr Earl Silverman (Hospital for Sick Children, Toronto, ONT) tells rheuma wire . “arava is an alternative to methotrexate and should be used in patients with JRA prior to death to a biologic.” Offset multicenter, randomized, double-blind examination This knowledge domain, which was conducted by members of the JRA Investigators Chemical group at 32 centers in 13 countries, randomized 94 JRA patients 3 to 17 gathering of age.
This is a part of article MTX, Arava both safe, more effective than expected in JRA Taken from "Arava Information" Information Blog